Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
about
Immunohistochemical correlates of TP53 somatic mutations in cancerTP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer.Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency.Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells.CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer.Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer.High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease.High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis.MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells.Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor MicroenvironmentTargeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
P2860
Q30360497-CAD97040-6006-45C0-8FB5-FC37BC2C683DQ37620902-D3C9923D-7D53-4D25-AF3F-529F71745A1BQ40340005-330E0286-D033-4036-818E-B4D36EA484AFQ41613769-131D69D9-EB82-4193-961A-6AED565C2009Q47407277-AE3BE41F-BCE1-493C-9750-F307A97A90DDQ48124146-F052BE3C-F85C-4298-AD59-FFA69C41B096Q48362485-712BE2F6-A93B-4092-A4C6-05E3DE07EDF9Q49688722-35843999-0E88-43E6-9E99-41D03626F088Q52667050-F0C4749C-3A4B-4082-AB51-B752C9599400Q52723469-87180408-5C50-4B4C-897C-46B4B60C1657Q52728031-BD87B5C5-B194-4686-AEF9-B87672767330Q55054132-C3763D82-E4CB-4643-988B-AF9C89CA9A3DQ55259197-71AD2AB5-8860-4E84-BA78-A40F6BC97D6EQ55332965-D598F734-C4FC-40E8-9A32-D30053EAE183Q55333460-FA581AAD-1555-4AA6-A830-27EBF553D192Q55347281-DF01CC76-ADCB-4703-B749-BFFA747BAFF0Q55364404-25F90337-6A7A-472F-B450-F20F88C14506Q55553003-15735C10-E6FE-4A14-8E6A-A7535921F094Q58773649-C0916419-DA91-4762-83CC-74ED86778E28Q58795530-B41DE2FA-1D6F-4903-B928-2105E6CEF1C1
P2860
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Assessing mutant p53 in primar ...... massively parallel sequencing.
@en
type
label
Assessing mutant p53 in primar ...... massively parallel sequencing.
@en
prefLabel
Assessing mutant p53 in primar ...... massively parallel sequencing.
@en
P2093
P2860
P356
P1433
P1476
Assessing mutant p53 in primar ...... massively parallel sequencing.
@en
P2093
Adele Clarkson
Alexander J Cole
Anthony J Gill
Deborah J Marsh
Gregory B Gard
Jayne Maidens
Kristie-Ann Dickson
Susan Valmadre
Trisha Dwight
P2860
P2888
P356
10.1038/SREP26191
P407
P577
2016-05-18T00:00:00Z
P6179
1047258317